Recent Developments at Biotechnology Companies: Special Research on Exelixis,ICON, Incyte, Luna Innovations, and Oncothyreon
NEW YORK, February 20, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Exelixis (NASDAQ: EXEL), ICON (NASDAQ: ICLR), Incyte (NASDAQ: INCY), Luna Innovations (NASDAQ: LUNA), and Oncothyreon (NASDAQ: ONTY). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being
made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
EXEL Research Report: ( http://get.analystsreview.com/pdf/?c=Exelixis&d=20-Feb-2015&s=EXEL ),
ICLR Research Report: ( http://get.analystsreview.com/pdf/?c=ICON&d=20-Feb-2015&s=ICLR ),
INCY Research Report: ( http://get.analystsreview.com/pdf/?c=Incyte&d=20-Feb-2015&s=INCY ),
LUNA Research Report: ( http://get.analystsreview.com/pdf/?c=Luna%20Innovations&d=20-Feb-2015&s=LUNA ),
ONTY Research Report: ( http://get.analystsreview.com/pdf/?c=Oncothyreon&d=20-Feb-2015&s=ONTY ).
============
--
Analyst Update: Upcoming Conference Calls, Acquisitions, Quarterly Results, Mergers, and License Agreements
Reviewed by: Rohit Tuli, CFA®
The US stock markets closed on a mixed note on Thursday. The Nasdaq rose for a seventh straight session boosted by a rally of 8.5% in the Priceline Group shares. The Dow and the S&P 500 on the other hand eased following declines in energy shares and a disappointing outlook from Wal-Mart. Uncertainty over prospects of a debt deal with Greece added to investor caution. Dow Jones Industrial Average closed down 44.08 points, or 0.24%, at 17,985.77; S&P 500 closed down 2.23 points, or 0.11%, at 2,097.45; while the Nasdaq closed up 18.34 points, or 0.37%, at 4,924.70. Europe's stock rally lost steam on Thursday, with a benchmark index retreating from a seven-year high, after Germany rejected a new proposal from Athens for an extension of its bailout programme. The German finance ministry described the Greek proposal as "not a substantial solution" because it failed to fulfill the conditions of an EU/IMF bailout programme. In Asia, the Nikkei rose to a 15-year high following better-than-expected export data, while trade in the rest of Asia was quiet with several markets closed for Lunar New Year.
Exelixis, Inc. (Exelixis) has scheduled to release its fourth quarter and full year 2014 financial results on Tuesday, February 24, 2015, after the markets closes. As per Zacks investment research, the Company is expected to report a net loss of $0.31 per share and $1.41 per share for Q4 and full-year 2014, respectively.
ICON plc (ICON) announced that it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions, a division of MediMedia USA, for a cash consideration of $120 million. According to the Company, the acquisition strengthens ICON's expertise in scientific communications and market access and, together with its existing Commercialisation and Outcomes practices, creates the industry's leading integrated scientific communications and market access solution.
Incyte Corporation (Incyte) recently announced its Q4 and full-year 2014 financial results. For Q4 2014, total revenues increased to $124.0 million compared to $97.1 million in Q4 2013. Net loss for the quarter narrowed to $37 million, or $0.22 per diluted share, compared to a net loss of $43 million, or $0.26 per diluted share, in Q4 2013. The Company also provided financial guidance for 2015.
Luna Innovations Incorporated (Luna Innovations) and Advanced Photonix, Inc. have announced their agreement to merge. The combined company will provide greater capability across a broader market base, with a strong balance sheet and potential operating synergies, said Luna Innovations. Also, the merged company will have pro forma combined revenue of approximately $49.9 million for the 12 months ended September 30, 2014, compared to Luna Innovations historical revenues of $20.0 million for the same period.
Oncothyreon Inc. (Oncothyreon) was recently granted exclusive license from Array BioPharma Inc. to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article